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Abstract 
 
Since the introduction of the concept that the noninvasive 
encapsulated follicular variant of papillary thyroid carcinoma does 
not warrant a diagnosis of carcinoma and shall be renamed 
noninvasive follicular thyroid neoplasm with papillary-like nuclear 
features (NIFTP), many questions have arisen among thyroid 
cytopathologists concerning the implications of this changing 
paradigm on the cytological classification of thyroid nodules. 
Specifically, whether it is possible to diagnose NIFTP by fine-
needle aspiration, how will the risk of malignancy of the diagnostic 
categories of thyroid cytopathology be affected, and which 
changes will be made to the current cytological workup of thyroid 
nodules. The aim of our work was to review published literature to 
analyze how cytopathologists are dealing with this changing 
paradigm in thyroid pathology and how, in turn, it is affecting their 
current practice. 
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Introduction 
 
Thyroid fine-needle aspiration (FNA) is an essential 
procedure in the initial evaluation and clinical management of 
thyroid nodules. Currently, most thyroid cytology specimens are 
classified in the frame of The Bethesda System for Reporting 
Thyroid Cytopathology (TBSRTC), which was introduced 
following the National Cancer Institute (NCI) Thyroid FNA State 
of the Science Conference held in Bethesda in 2007 (Table 1). 
Other national systems exist (in Japan, Italy, United Kingdom, and 
Australia); the common endeavor of all being the effort to address 
terminology issues related to thyroid FNA and to make reporting 
of thyroid FNA uniform across different laboratories (1).  
Independently of the reporting system used, thyroid FNA 
serves as a diagnostic test in cases of benign proliferations, 
papillary thyroid carcinomas (PTCs) and other malignancies, but it 
is best considered as a screening test for follicular-patterned 
lesions,   including   hyperplastic   nodules,   follicular   adenomas,  
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Table 1. The Bethesda System for Reporting Thyroid Cytopathology 
diagnostic categories with implied risk of malignancy and recommended 
clinical management* 
Diagnostic Category Risk of Malignancy Usual Management 
I. Nondiagnostic or 
Unsatisfactory 
1-4% Repeat FNA with 
ultrasound guidance 
II. Benign 0-3% Clinical follow-up 
III. Atypia of Undetermined 
Significance or Follicular 
Lesion of Undetermined 
Significance 
~5-15% Repeat FNA 
IV. Follicular Neoplasm or 
Suspicious for a Follicular 
Neoplasm 
15-30% Surgical lobectomy 
V. Suspicious for Malignancy 60-75% Near-total 
thyroidectomy or 
surgical lobectomy 
VI. Malignant 97-99% Near-total 
thyroidectomy 
FNA, fine-needle aspiration; *Adapted from Cibas et al. (1). 
 
follicular carcinomas, and a number of follicular variants of PTC. 
FNA has a limited accuracy in these lesions because of 
overlapping cytomorphological features among them and because 
histopathological examination is required to establish a definitive 
diagnosis (2). 
 
Noninvasive Thyroid Neoplasm with Papillary-like 
Nuclear Features: A Paradigm Shift Affecting Thyroid 
Cytopathology 
 
During the Endocrine Pathology Society’s conference held in 
Boston, Massachusetts, in March 2015, a working group composed 
of well-known and experienced pathologists re-evaluated the 
concept of noninvasive encapsulated follicular variant of PTC 
(EFVPTC). They concluded that these tumors were to be renamed 
“noninvasive   follicular   thyroid   neoplasm   with    papillary-like 
nuclear features” (NIFTP), on the basis of the uneventful clinical 
course of these patients during follow-up (3, 4). Since then, critical 
questions have arisen among thyroid cytopathologists concerning 
the impact of this changing paradigm on the cytological 
classification of thyroid nodules, notably: 
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Table 2. Cytological features allowing NIFTP to be distinguished from other thyroid lesions 
 
Authors Cytological Features Associated with NIFTP Is NIFTP Differential Diagnosis Possible on Cytology? 
Maletta et al. 
(6) 
The presence of: 
-­‐ Nuclear enlargement 
-­‐ Nuclear membrane irregularities 
-­‐ Optically clear, ground glass nuclei 
-­‐ Nuclear molding 
shows statistical significance in distinguishing NIFTP from benign adenomas. 
Possible: NIFTP vs. FA. 
 
Strickland et al. 
(10) 
 
In cases raising concern for PTC because of characteristic nuclear features, the presence of: 
-­‐ Abundant papillae and intranuclear pseudoinclusions is significantly associated with PTC; 
-­‐ A predominantly microfollicular pattern, is significantly associated with NIFTP and I-FVPTC. 
 
Possible: NIFTP vs. PTC. 
 
Ibrahim and Wu 
(7) 
 
I-FVPTC shows higher cellularity and more obvious nuclear aberrations as compared with NIFTP, 
which presents lower cellularity and subtle nuclear changes. 
 
Possible: NIFTP vs. I-FVPTC. 
 
Bizzarro et al. 
(8) 
 
A higher number of follicular clusters with <10 thyrocytes is associated with NIFTP as compared 
with I-FVPTC; 
Cytoplasmic volume is low in NIFTP as compared to FA; 
Nuclear size <20 µm permits distinction of NIFTP from FA and PTC. 
 
Possible: NIFTP vs. I-FVPTC. 
Possible: NIFTP vs. FA and PTC 
 
NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; FA, follicular adenoma; I-FVPTC, invasive follicular variant of 
papillary thyroid carcinoma; PTC, papillary thyroid carcinoma. 
  
 
1)  Is it possible to diagnose NIFTP by thyroid FNA 
cytology?  
2)  How will the change in terminology affect the current 
practice of thyroid FNA cytology, and specifically the 
risk of malignancy (ROM) of the different diagnostic 
categories? 
3)  How will the current management algorithm be 
associated with each diagnostic category change? 
Over the months that followed the introduction of NIFTP as a 
new diagnostic entity, numerous papers were published as thyroid 
cytopathologists strived to answer these questions. We report a 
summary of the main findings, which could be useful in daily 
cytopathology practice. 
 
Diagnosis of NIFTP on Thyroid FNA 
 
Definition of the role of cytopathology in the diagnosis of 
NIFTP and characterization of the cytomorphological features that 
could help in correctly identifying these lesions on FNA material 
have been a main focus of thyroid cytopathologists since the 
proposal of noninvasive EFVPTC reclassification. Table 2 
summarizes the results of studies on the cytological diagnosis of 
NIFTP.  
Maletta et al. assessed a series of cytological parameters and 
found that nuclear enlargement, nuclear membrane irregularities, 
optically clear, ground glass nuclei, and nuclear molding showed 
statistical significance in distinguishing NIFTPs from benign 
adenomas on FNA cytology. Among these parameters, the first 
three are the same criteria applied by Nikiforov and colleagues in 
their score for evaluating NIFTP histology (3, 5). 
Strickland and colleagues compared FNA of cases 
histologically diagnosed as noninvasive EFVPTCs and classical 
PTCs and scored them for a series of features. They found that, in 
cases where nuclear features already raised significant concerns for 
a diagnosis of PTC, the presence of abundant papillae and nuclear 
pseudoinclusions was significantly associated with PTC, whereas a 
predominantly microfollicular pattern was associated with NIFTP 
and a follicular variant of PTC (FVPTC). They therefore 
recommended that such parameters be used by cytopathologists to 
triage patients with putative NIFTP for consideration of diagnostic 
lobectomy while recognizing patients with putative classical PTC 
who need total thyroidectomy (6). 
Ibrahim and Wu compared FNA diagnoses of noninvasive 
EFVPTC/NIFTPs versus invasive EFVPTC and infiltrative 
FVPTC, and noted a clear difference between the two groups: 
whereas the invasive EFVPTC and the infiltrative FVPTC 
subtypes were diagnosed in almost 75% of cases as suspicious for 
malignancy or malignant, 4% and 0% of noninvasive 
EFVPTC/NIFTPs were classified as suspicious for malignancy or 
were malignant, respectively. The authors suggest that a 
cytomorphological distinction exists between invasive and 
noninvasive EFVPTC, with invasive EFVPTC showing higher 
cellularity and more obvious nuclear aberrations as compared to 
noninvasive EFVPTC/NIFTP, which displays subtle nuclear 
changes and an overall lower cellularity (7). 
Bizzarro et al. analyzed a number of architectural, 
cytoplasmic and nuclear features, and compared them in a series of 
noninvasive EFVPTCs/NIFTPs, invasive EFVPTCs, follicular 
adenomas (FAs) and PTCs. From an architectural point of view, 
they found that NIFTPs as well as invasive EFVPTCs lacked 
papillary structures on cytology and were characterized instead by 
follicular clusters. When they considered the number of thyrocytes 
in such clusters, a slightly higher number of clusters with <10 cells 
were associated with NIFTP compared to invasive EFVPTC. 
Among the analyzed cytoplasmic parameters, low cytoplasmic 
volume of NIFTP as compared to FA was the only one that 
reached statistical significance. A nuclear size cutoff of <20 µm 
was statistically significant in distinguishing NIFTPs from FAs and 
PTCs, but not from invasive EFVPTCs. The authors also proposed 
a diagnostic algorithm to detect NIFTP by combining 
cytomorphological features with the results of an 
immunocytochemical panel (8).  
A provisional approach for cytopathologists in dealing with 
NIFTP has been suggested by Krane and colleagues in a 
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commentary published in Cancer Cytopathology (9). According to 
them, when the evaluation of NIFTP is performed within the 
framework of TBSRTC, features that suggest NIFTP by FNA (i.e., 
lesions presenting microfollicular architecture with enlarged 
nuclei, pale chromatin, irregular membranes with nuclear grooves 
but lacking intranuclear pseudoinclusions, psammoma bodies or 
papillae) should be used to minimize the classification of potential 
NIFTP cases as malignant. The diagnosis of Bethesda VI 
(malignant, PTC) should be limited to cases with frequent 
intranuclear pseudoinclusions, papillae or psammoma bodies (9). 
 
Impact of the NIFTP Proposal on the Practice of 
Thyroid FNA Cytology and ROM of Diagnostic 
Categories of TBSRTC 
 
The ROM for each diagnostic category of TBSRTC has been 
defined with noninvasive EFVPTC being considered as a 
malignancy; the reclassification of this lesion as NIFTP is 
therefore expected to modify the ROM of the diagnostic categories 
to which noninvasive EFVPTC/NIFTP is currently allocated.  
This issue has been addressed by Strickland et al. and Faquin 
and colleagues, who evaluated the impact of noninvasive EFVPTC 
reclassification as a benign lesion on the ROM for each of the 6 
current diagnostic categories of TBSRTC. The former group 
analyzed a cohort of 655 FNAs with subsequent resection 
specimens and found the following decrease in the rate of 
malignancy: 1.9% for non-diagnostic; 7.8% for benign; 17.6% for 
atypia of undetermined significance/follicular lesion of 
undetermined significance (AUS/FLUS); 8% for follicular 
neoplasm/suspicious for a follicular neoplasm (FN/SFN); 41.5% 
for suspicious for malignancy (SM); and 5.1% for the malignant 
category (10). In a large multi-institutional cohort of thyroid FNA 
cases, Faquin et al. investigated a study cohort of 6943 nodules, 
26.3% of which (n = 1827) with corresponding surgical resection 
specimen; exclusion of noninvasive EFVPTC from the calculation 
of the ROM led to the following decrease in the ROM: 1.4% for 
non-diagnostic cases; 3.5% for cases diagnosed as benign; 13.6% 
for AUS/FLUS cases; 15.1% for FN/SFN cases; 23.4% for cases 
SM; and 3.3% for malignant cases. The majority of noninvasive 
EFVPTC FNA cases were diagnosed in one of the indeterminate 
categories (AUS/FLUS, FN/SFN and SM), for which the greatest 
decrease in ROM was observed (11). 
Before the introduction of NIFTP as a diagnostic entity, non-
invasive encapsulated follicular tumors with equivocal PTC type 
nuclear changes were classified by some authors as “well-
differentiated tumors of uncertain malignant potential” (WDT-
UMP), a possible borderline thyroid lesion. In reason of its 
questionable nuclear features, including faint nuclear grooves and 
uncompelling nuclear vacuoles, WDT-UMP was most often found 
in the indeterminate cytological categories, as shown by Nishigami 
and colleagues (12). 
The magnitude of the impact that reclassification of 
noninvasive EFVPTC into NIFTP will have is difficult to predict; 
overall, for each institution, the decrease in ROM implied by each 
of the diagnostic categories of TBSRTC is expected to be affected 
by patient demographics and by the institutional frequency of 
rendering a noninvasive EFVPTC diagnosis (13). 
 
Impact of NIFTP Proposal on Cytologic Workup of 
Thyroid FNA 
 
A significant decrease in the ROM for the indeterminate 
categories may lead to a change in the management paradigm of 
thyroid nodules that can affect the workup of cytological 
specimens. 
In this context, the application of targeted molecular tests to 
FNA material can help in providing management tailored to the 
individual patient. In fact, Nikiforov and colleagues have shown 
that noninvasive EFVPTC/NIFTP demonstrates a high prevalence 
of RAS mutations, which are generally associated with follicular-
patterned thyroid tumors, including FA, follicular thyroid 
carcinoma and encapsulated FVPTC (13); this is unlike classical 
PTC and infiltrative FVPTC, whose most frequent genetic 
alteration is a BRAF mutation (14). 
In case of nodules with indeterminate cytology that harbor a 
RAS mutation, a simple lobectomy can be proposed. If, on the 
contrary, a lesion of indeterminate cytology shows the presence of 
a BRAF mutation, then a total thyroidectomy can be advised. The 
main problem of this approach is the low frequency of mutations in 
thyroid nodules.  
A different approach can involve the application of 
commercially available tests to FNA material: Jiang et al. have 
evaluated the performance of the Afirma gene expression classifier 
(GEC) and the ThyroSeq panel in a series of 8 NIFTPs, all of 
which had been classified as Bethesda III or IV preoperatively. 
The four nodules investigated by Afirma GEC were all identified 
as “suspicious”, whereas the four nodules evaluated by ThyroSeq 
harbored RAS mutations. Both the GEC and the ThyroSeq 
methods indicated abnormalities in NIFTP. Therefore, according to 
the authors, further study is needed to better classify the molecular 
characteristics of NIFTP (15). 
 
Our Experience 
 
We were surprised by the high prevalence of NIFTP reported 
by Nikiforov and colleagues: 13.6% in the Bellaria Hospital, 
Bologna, Italy (2000-2015); 25% in San Luigi Hospital, Turin, 
Italy (2005-2014); 18.7% in Hospital of Pisa, Pisa, Italy (2000-
2004); and 18.8% in MSKCC, New York, USA (2000-2003), for a 
mean value of 18.6% (3). We therefore decided to review our cases 
of surgically resected thyroid cancer to see how frequent NIFTP 
was in the mountain region of the Swiss Canton of Vaud and, 
therefore, how often we should expect to encounter NIFTP in our 
cytological samples. In the 6-year period comprised between 
January 1st 2011 and December 31st 2016, for a total number of 
216 thyroid cancers, we diagnosed only 9 noninvasive 
EFVPTCs/NIFTPs, accounting for 4.2% of thyroid carcinomas 
diagnosed at our Institution. Pre-operative cytology was available 
for 5 of these 9 cases: one was diagnosed as a benign cyst; two as 
FN/SFN; one as suspicious for PTC; and one as PTC. 
A similar prevalence of EFVPTC had been described by 
Piana and coworkers in 2010, years before the NIFTP proposal, in 
the Department of Pathology of the Arcispedale Santa Maria 
Nuova, Reggio Emilia, Italy: EFVPTC represented 4.5% of thyroid 
carcinomas diagnosed over a period of 25 years comprised 
between 1979 and 2004 (16). 
Similarly, Liu et al. reported an even lower diagnostic rate in 
the Department of Pathology of the Wakayama Medical 
University, Wakayama, Japan: there, EFVPTC accounted for 0.4% 
of thyroid cancers diagnosed between 1990 and 2009 (17). 
 
Conclusions 
 
For the time being, NIFTP remains a surgical disease that, in 
our opinion, cannot be diagnosed on cytological grounds. NIFTP 
diagnosis can only be provided upon surgical excision. One of the 
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main concerns for cytopathologists, regarding the reclassification 
of noninvasive EFVPTC into NIFTP, is the increase in the “false 
positive” rates and the possible medicolegal implications. Most 
clinicians would advise total thyroidectomy for cases diagnosed 
cytologically as suspicious or compatible with PTC because of the 
high ROM associated with these cytological diagnoses. From the 
histology, some of these cases will turn out to be NIFTP (and 
benign) (12). 
This is why the decrease of ROM deriving from the 
reclassification of noninvasive EFVPTC into NIFTP, especially 
affecting the indeterminate categories, will lead to a modification 
in the pre-surgical management algorithm associated with 
TBSRTC, with the potential implementation of molecular testing 
to distinguish indeterminate nodules at high risk of being 
malignant from those at low risk. A different approach could 
consist in the discussion of individual cases in the 
multidisciplinary setting of a tumor board: by combining 
cytological, clinical, ultra-sound and molecular features, the risk of 
malignancy for each patient can be better evaluated. 
  
References 
 
1. Cibas ES, Ali SZ. The Bethesda System for Reporting 
Thyroid Cytopathology. Am J Clin Pathol 2009; 132:658-65. 
2. Faquin WC, Baloch ZW. Fine-needle aspiration of follicular 
patterned lesions of the thyroid: diagnosis, management, and 
follow-up according to National Cancer Institute (NCI) 
recommendations. Diagn Cytopathol 2010; 38:731-9. 
3. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, 
Thompson LDR, Barletta JA, Wenig BM, Al Ghuzlan A, 
Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, 
El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal 
G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, 
Sadow PM, Tischler AS, Tuttle M, Wall KB, LiVolsi VA, 
Randolph GW, Ghossein RA. Nomenclature revision for 
encapsulated follicular variant of papillary thyroid carcinoma: 
a paradigm shift to reduce overtreatment of indolent tumors. 
JAMA Oncol 2016; 2:1023-9. 
4. Patel KN. Noninvasive encapsulated follicular variant of 
papillary thyroid "cancer" (or not): time for a name change. 
JAMA Oncol 2016; 2:1005-6. 
5. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, 
Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. 
Cytological features of "non-invasive follicular thyroid 
neoplasm with papillary-like nuclear features" and their 
correlation with tumor histology. Hum Pathol 2016; 54:134-
42. 
6. Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas 
ES, Krane JF, Barletta JA. Preoperative cytologic diagnosis of 
noninvasive follicular thyroid neoplasm with papillary-like 
nuclear features: a prospective analysis. Thyroid 2016; 
26:1466-71. 
7. Ibrahim AA, Wu HH. Fine-needle aspiration cytology of 
noninvasive follicular variant of papillary thyroid carcinoma 
is cytomorphologically distinct from the invasive counterpart. 
Am J Clin Pathol 2016; 146:373-7. 
8. Bizzarro T, Martini M, Capodimonti S, Straccia P, Lombardi 
CP, Pontecorvi A, Larocca LM, Rossi ED. Young investigator 
challenge: the morphologic analysis of noninvasive follicular 
thyroid neoplasm with papillary-like nuclear features on 
liquid-based cytology: some insights into their identification. 
Cancer Cytopathol 2016; 124:699-710. 
9. Krane JF, Alexander EK, Cibas ES, Barletta JA. Coming to 
terms with NIFTP: a provisional approach for cytologists. 
Cancer Cytopathol 2016; 124:767-72. 
10. Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas 
ES, Krane JF, Barletta JA. The impact of noninvasive 
follicular variant of papillary thyroid carcinoma on rates of 
malignancy for fine-needle aspiration diagnostic categories. 
Thyroid 2015; 25:987-92. 
11. Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, 
Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, 
Gourmaud J, Vaickus LJ, Baloch ZW. Impact of reclassifying 
noninvasive follicular variant of papillary thyroid carcinoma 
on the risk of malignancy in The Bethesda System for 
Reporting Thyroid Cytopathology. Cancer Cytopathol 2016; 
124:181-7. 
12. Nishigami K, Liu Z, Taniguchi E, Koike E, Ozaki T, Mori I, 
Kakudo K. Cytological features of well-differentiated tumors 
of uncertain malignant potential: indeterminate cytology and 
WDT-UMP. Endocr J 2012; 59:483-7. 
13. Baloch ZW, Seethala RR, Faquin WC, Papotti MG, Basolo F, 
Fadda G, Randolph GW, Hodak SP, Nikiforov YE, Mandel 
SJ. Noninvasive follicular thyroid neoplasm with papillary-
like nuclear features (NIFTP): a changing paradigm in thyroid 
surgical pathology and implications for thyroid 
cytopathology. Cancer Cytopathol 2016; 124:616-20. 
14. Cancer Genome Atlas Research Network. Integrated genomic 
characterization of papillary thyroid carcinoma. Cell 2014; 
159:676-90. 
15. Jiang XS, Harrison GP, Datto MB. Young investigator 
challenge: molecular testing in noninvasive follicular thyroid 
neoplasm with papillary-like nuclear features. Cancer 
Cytopathol 2016; 124:893-900. 
16. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai 
J. Encapsulated well-differentiated follicular-patterned 
thyroid carcinomas do not play a significant role in the fatality 
rates from thyroid carcinoma. Am J Surg Pathol 2010; 
34:868-72. 
17. Liu Z, Zhou G, Nakamura M, Koike E, Li Y, Ozaki T, Mori I, 
Taniguchi E, Kakudo K. Encapsulated follicular thyroid 
tumor with equivocal nuclear changes, so-called well-
differentiated tumor of uncertain malignant potential: a 
morphological, immunohistochemical, and molecular 
appraisal. Cancer Sci 2011; 102:288-94. 
 
